Anticoagulating New-Onset Atrial Fibrillation After COVID-19: A Single-Center Experience
Description
Anticoagulation (AC) strategy in new-onset atrial fibrillation (NOAF) secondary to other illnesses has not been broadly studied, and society-level guidance does not provide a strong recommendation regarding outpatient continuation upon discharge. Our
